Metabolic complications associated with use of diuretics

Seminars in Nephrology

Volumn 31, Issue 6, 2011, Pages 542-552

  Palmer, Biff F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Diuretics; Furosemide; Hyperkalemia; Hypokalemia; Metabolic alkalosis; Thiazide

Indexed keywords

ACETAZOLAMIDE; ALLOPURINOL; AMILORIDE; AMMONIUM CHLORIDE; BICARBONATE; CALCIUM; CARBONATE DEHYDRATASE INHIBITOR; CHLORIDE; ELECTROLYTE; LOOP DIURETIC AGENT; MAGNESIUM; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; OSMOTIC DIURETIC AGENT; POTASSIUM; POTASSIUM CHLORIDE; POTASSIUM SPARING DIURETIC AGENT; PROTON; SODIUM; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; URIC ACID; WATER;

ARTICLE; BIOCHEMISTRY; CHLORIDE TRANSPORT; DISORDERS OF ACID BASE BALANCE; DIURESIS; DYSLIPIDEMIA; ELECTROLYTE DISTURBANCE; GOUT; HEART ARRHYTHMIA; HENLE LOOP; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOCALCIURIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMPAIRED GLUCOSE TOLERANCE; INDIVIDUALIZATION; KIDNEY TUBULE ABSORPTION; MEDICAL DECISION MAKING; METABOLIC ACIDOSIS; METABOLIC ALKALOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; SALT INTAKE; SODIUM TRANSPORT; SUDDEN DEATH; WATER TRANSPORT;

ACID-BASE IMBALANCE; ACIDOSIS; DIURETICS; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOKALEMIA; METABOLIC DISEASES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 81355164021     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2011.09.009     Document Type: Article

References (46)

1. Stanton B.A. Cellular actions of thiazides in the distal tubule. J Am Soc Nephrol 1990, 1:832-836.
2. Ernst M., Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2010, 361:2153-2164.
3. Hebert S.C., Desir G., Giebisch G., Wang W. Molecular diversity and regulation of renal potassium channels. Physiol Rev 2005, 85:319-371.
4. Giebisch G., Krapf R., Wagner C. Renal and extrarenal regulation of potassium. Kidney Int 2007, 72:397-410.
5. Komlosi P., Fintha A., Bell P.D. Current mechanisms of macula densa cell signalling. Acta Physiol Scand 2004, 181:463-469.
6. Ram C.V., Garrett B.N., Kaplan N.M. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981, 141:1015-1019.
7. van Brummelen P., Schalekamp M., de Graeff J. Influence of sodium intake on hydrochlorothiazide-induced changes in blood pressure, serum electrolytes, renin and aldosterone in essential hypertension. Acta Med Scand 1978, 204:151-157.
8. Guntupalli J., Onuigbo M., Wall S., Alpern R.J., DuBose T.D. Adaptation to low-K+ media increases H(+)-K(+)-ATPase but not H(+)-ATPase-mediated pHi recovery in OMCD1 cells. Am J Physiol 1997, 273:C558-C571.
9. Kassirer J.P., Harrington J.T. Diuretics and potassium metabolism: a reassessment of the need, effectiveness and safety of potassium therapy. Kidney Int 1977, 11:505-515.
10. Papademetriou V. Diuretics, hypokalemia, and cardiac arrhythmia: a 20 year controversy. J Clin Hypertens 2006, 8:86-92.
11. Siscovick D.S., Raghunathan T.E., Psaty B.M., Koepsell T.D., Wicklund K.G., Lin X., et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994, 330:1852-1857.
12. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264. SHEP Cooperative Research Group.
13. Dahlof B., Lindholm L.H., Hansson L., Schersten B., Ekbom T., Wester P.O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991, 338:1281-1285.
14. Psaty B.M., Smith N.L., Siscovick D.S., Koepsell T.D., Weiss N.S., Heckbert S.R., et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997, 277:739-745.
15. Kaplan N.M., Carnegie A., Raskin P., Heller J.A., Simmons M. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med 1985, 312:746-749.
16. Smith N.L., Lemaitre R.N., Heckbert S.R., Kaplan R.C., Tirschwell D.L., Longstreth W.T., et al. Serum potassium and stroke risk among treated hypertensive adults. Am J Hypertens 2003, 16:806-813.
17. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004, 351:585-592.
18. Schrier R.W. Hyperkalemia: a threat to RAAS inhibition. Nat Rev Nephrol 2010, 6:245-246.
19. Palmer B.F. Physiology and pathophysiology with ascent to altitude. Am J Med Sci 2010, 340:69-77.
20. Palmer B.F., Alpern R.J. Metabolic alkalosis. J Am Soc Nephrol 1997, 8:1462-1469.
21. Anzai N., Kanai Y., Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007, 19:151-157.
22. Rafey M.A., Lipkowitz M.S., Leal-Pinto E., Abramson R.G. Uric acid transport. Curr Opin Nephrol Hypertens 2003, 12:511-516.
23. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002, 417:447-451.
24. Hasannejad H., Takeda M., Taki K., et al. Interactions of human organic anion transporters with diuretics. J Pharm Exp Ther 2004, 308:1021-1029.
25. Hagos Y., Stein D., Ugele B., Burckhardt G., Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007, 18:430-439.
26. Reyes A. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003, 17:397-414.
27. Cauley J., Cummings S., Seeley D., Black D., Browner W., Kuller L., et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The study of osteoporotic fractures research group. Ann Intern Med 1993, 118:666-673.
28. LaCroix, Wienpahl J., White L., et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990, 322:286-290.
29. Friedman P.A. Codependence of renal calcium and sodium transport. Annu Rev Physiol 1998, 60:179-197.
30. Hoenderop J., Nilius B., Bindels R. Epithelial calcium channels: from identification to function and regulation. Pflugers Arch 2003, 446:304-308.
31. Nijenhuis T., Hoenderop J., Bindels R. TRPV5 and TRPV6 in Ca (2+) (re)absorption: regulating Ca (2+) entry at the gate. Pflugers Arch 2005, 451:181-192.
32. Loffing J., Loffing-Cueni D., Hegyi I., et al. Thiazide treatment of rates provokes apoptosis in distal tubule cells. Kidney Int 1996, 50:1180-1190.
33. Nijenhuis T., Vallon V., van der Kemp A.W., Loffing J., Hoenderop J.G., Bindels R.J. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 2005, 115:1651-1658.
34. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. N Engl J Med 1987, 317:350-357.
35. Pollare T., Lithell H., Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990, 39:167-174.
36. Reaven G.M. Relationship between insulin resistance and hypertension. Diabetes Care 1991, 14(Suppl 4):33-38.
37. Messerli F.H., Grossman E., Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004, 22:1845-1847.
38. Mason J.M., Dickinson H.O., Nicolson D.J., Campbell F., Ford G.A., Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005, 23:1777-1781.
39. Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3-10.
40. Chatterjee R., Yeh H., Shafi T., Selvin S., et al. Serum and dietary potassium and risk of incident type 2 diabetes mellitus. Arch Intern Med 2010, 170:1745-1751.
41. Zillich A., Garg J., Basu S., Bakris G., Carter B. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48:219-224.
42. Cutler J. Thiazide-associated glucose abnormalities: prognosis, etiology, and prevention: is potassium balance the key. Hypertension 2006, 48:198-200.
43. ATP channels in pancreatic beta cells underlies a spectrum of diabetic phenotypes. Diabetes 2006, 55:2957-2964.
44. Barzilay J., Cutler J., Davis B. Antihypertensive medications and risk of diabetes mellitus. Curr Opin Nephrol Hypertens 2007, 16:256-260.
45. van Brummelen P., Gevers Leuven J.A., van Gent C.M. Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. Curr Med Res Opin 1979, 6:24-29.
46. Weir M.R., Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia?. Am Heart J 2000, 139:174-183.